Skip to Content

Arepanrix

Active Substance: split influenza virus, inactivated, containing antigen* : A/California/7/2009 (H1N1)v like strain (X-179A) * produced in eggs
Common Name: pandemic influenza vaccine (H1N1) (split virion, inactivated, adjuvanted)
ATC Code: J07BB02
Marketing Authorisation Holder: GlaxoSmithKline Biologicals S.A.
Active Substance: split influenza virus, inactivated, containing antigen* : A/California/7/2009 (H1N1)v like strain (X-179A) * produced in eggs
Status: Withdrawn
Authorisation Date: 2010-03-23
Therapeutic Area: Influenza, Human Immunization Disease Outbreaks
Pharmacotherapeutic Group: Influenza vaccines

Therapeutic Indication

Prophylaxis of influenza in an officially declared pandemic situation. Pandemic influenza vaccine should be used in accordance with official guidance

The marketing authorisation for Arepanrix has been withdrawn at the request of the marketing authorisation holder.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide